APO Research
Talk to an analyst

APO RESEARCH · REPORT

Complement Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Complement Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025190 pages

Choose your research edition.

Industry ResearchComplement Inhibitors Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement Inhibitors Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Complement Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement Inhibitors Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement Inhibitors Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Complement Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Complement Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Complement Inhibitors include Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas Pharma, CSL Behring, Pharming Healthcare, Regeneron Pharmaceuticals, Samsung Bioepis and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Complement Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Complement Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Complement Inhibitors Segment by Company

Alexion Pharmaceuticals

Amgen

Apellis Pharmaceuticals

Astellas Pharma

CSL Behring

Pharming Healthcare

Regeneron Pharmaceuticals

Samsung Bioepis

UCB

Roche

Novartis

Sanofi

Takeda

Complement Inhibitors Segment by Type

Complement Factor D Inhibitor

Complement Factor B Inhibitor

Complement C5 Inhibitors

Complement C3 Inhibitors

C1 Esterase Inhibitors

Complement Inhibitors Segment by Application

Geographic Atrophy (GA)

Atypical Hemolytic Uremic Syndrome (aHUS)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Others

Complement Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Complement Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Complement Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Complement Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Complement Inhibitors Industry Trends Table 2. Complement Inhibitors Industry Drivers Table 3. Complement Inhibitors Industry Opportunities and Challenges Table 4. Complement Inhibitors Industry Restraints Table 5. Global Complement Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Complement Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Complement Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Complement Inhibitors Sales Market Share by Manufacturers Table 9. Global Complement Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Complement Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Complement Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Complement Inhibitors Manufacturers, Product Type & Application Table 13. Global Complement Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Complement Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Complement Factor D Inhibitor Table 17. Major Manufacturers of Complement Factor B Inhibitor Table 18. Major Manufacturers of Complement C5 Inhibitors Table 19. Major Manufacturers of Complement C3 Inhibitors Table 20. Major Manufacturers of C1 Esterase Inhibitors Table 21. Global Complement Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Complement Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Global Complement Inhibitors Sales by Type (2027-2032) & (K Units) Table 24. Global Complement Inhibitors Sales Market Share by Type (2021-2026) Table 25. Global Complement Inhibitors Sales Market Share by Type (2027-2032) Table 26. Global Complement Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Complement Inhibitors Revenue by Type (2021-2026) & (K Units) Table 28. Global Complement Inhibitors Revenue by Type (2027-2032) & (K Units) Table 29. Global Complement Inhibitors Revenue Market Share by Type (2021-2026) Table 30. Global Complement Inhibitors Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Geographic Atrophy (GA) Table 32. Major Manufacturers of Atypical Hemolytic Uremic Syndrome (aHUS) Table 33. Major Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 34. Major Manufacturers of Others Table 35. Global Complement Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Complement Inhibitors Sales by Application (2021-2026) & (K Units) Table 37. Global Complement Inhibitors Sales by Application (2027-2032) & (K Units) Table 38. Global Complement Inhibitors Sales Market Share by Application (2021-2026) Table 39. Global Complement Inhibitors Sales Market Share by Application (2027-2032) Table 40. Global Complement Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Complement Inhibitors Revenue by Application (2021-2026) & (K Units) Table 42. Global Complement Inhibitors Revenue by Application (2027-2032) & (K Units) Table 43. Global Complement Inhibitors Revenue Market Share by Application (2021-2026) Table 44. Global Complement Inhibitors Revenue Market Share by Application (2027-2032) Table 45. Global Complement Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Complement Inhibitors Sales by Region (2021-2026) & (K Units) Table 47. Global Complement Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Complement Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Complement Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Complement Inhibitors Sales by Country (2021-2026) & (K Units) Table 52. North America Complement Inhibitors Sales by Country (2027-2032) & (K Units) Table 53. Europe Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Complement Inhibitors Sales by Country (2021-2026) & (K Units) Table 55. Europe Complement Inhibitors Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Complement Inhibitors Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Complement Inhibitors Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Complement Inhibitors Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Complement Inhibitors Sales by Country (2027-2032) & (K Units) Table 62. Global Complement Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Complement Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Complement Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Complement Inhibitors Revenue Market Share by Region (2021-2026) Table 66. Global Complement Inhibitors Revenue Market Share by Region (2027-2032) Table 67. Alexion Pharmaceuticals Company Information Table 68. Alexion Pharmaceuticals Business Overview Table 69. Alexion Pharmaceuticals Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Alexion Pharmaceuticals Complement Inhibitors Product Portfolio Table 71. Alexion Pharmaceuticals Recent Development Table 72. Amgen Company Information Table 73. Amgen Business Overview Table 74. Amgen Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Amgen Complement Inhibitors Product Portfolio Table 76. Amgen Recent Development Table 77. Apellis Pharmaceuticals Company Information Table 78. Apellis Pharmaceuticals Business Overview Table 79. Apellis Pharmaceuticals Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Apellis Pharmaceuticals Complement Inhibitors Product Portfolio Table 81. Apellis Pharmaceuticals Recent Development Table 82. Astellas Pharma Company Information Table 83. Astellas Pharma Business Overview Table 84. Astellas Pharma Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Astellas Pharma Complement Inhibitors Product Portfolio Table 86. Astellas Pharma Recent Development Table 87. CSL Behring Company Information Table 88. CSL Behring Business Overview Table 89. CSL Behring Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. CSL Behring Complement Inhibitors Product Portfolio Table 91. CSL Behring Recent Development Table 92. Pharming Healthcare Company Information Table 93. Pharming Healthcare Business Overview Table 94. Pharming Healthcare Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pharming Healthcare Complement Inhibitors Product Portfolio Table 96. Pharming Healthcare Recent Development Table 97. Regeneron Pharmaceuticals Company Information Table 98. Regeneron Pharmaceuticals Business Overview Table 99. Regeneron Pharmaceuticals Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Regeneron Pharmaceuticals Complement Inhibitors Product Portfolio Table 101. Regeneron Pharmaceuticals Recent Development Table 102. Samsung Bioepis Company Information Table 103. Samsung Bioepis Business Overview Table 104. Samsung Bioepis Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Samsung Bioepis Complement Inhibitors Product Portfolio Table 106. Samsung Bioepis Recent Development Table 107. UCB Company Information Table 108. UCB Business Overview Table 109. UCB Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. UCB Complement Inhibitors Product Portfolio Table 111. UCB Recent Development Table 112. Roche Company Information Table 113. Roche Business Overview Table 114. Roche Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Roche Complement Inhibitors Product Portfolio Table 116. Roche Recent Development Table 117. Novartis Company Information Table 118. Novartis Business Overview Table 119. Novartis Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Novartis Complement Inhibitors Product Portfolio Table 121. Novartis Recent Development Table 122. Sanofi Company Information Table 123. Sanofi Business Overview Table 124. Sanofi Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Sanofi Complement Inhibitors Product Portfolio Table 126. Sanofi Recent Development Table 127. Takeda Company Information Table 128. Takeda Business Overview Table 129. Takeda Complement Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Takeda Complement Inhibitors Product Portfolio Table 131. Takeda Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Complement Inhibitors Distributors List Table 135. Complement Inhibitors Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Complement Inhibitors Product Image Figure 2. Global Complement Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Complement Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Complement Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Complement Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Complement Factor D Inhibitor Image Figure 9. Complement Factor B Inhibitor Image Figure 10. Complement C5 Inhibitors Image Figure 11. Complement C3 Inhibitors Image Figure 12. C1 Esterase Inhibitors Image Figure 13. Global Complement Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Complement Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Complement Inhibitors Sales Market Share by Type (2021-2032) Figure 16. Global Complement Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Complement Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Complement Inhibitors Revenue Market Share by Type (2021-2032) Figure 19. Geographic Atrophy (GA) Image Figure 20. Atypical Hemolytic Uremic Syndrome (aHUS) Image Figure 21. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 22. Others Image Figure 23. Global Complement Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Complement Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Complement Inhibitors Sales Market Share by Application (2021-2032) Figure 26. Global Complement Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Complement Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Complement Inhibitors Revenue Market Share by Application (2021-2032) Figure 29. North America Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Complement Inhibitors Sales Market Share by Country (2021-2032) Figure 31. U.S. Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Complement Inhibitors Sales Market Share by Country (2021-2032) Figure 36. Germany Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Complement Inhibitors Sales Market Share by Country (2021-2032) Figure 43. China Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Complement Inhibitors Sales Market Share by Country (2021-2032) Figure 51. Brazil Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Complement Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Complement Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Complement Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Complement Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. North America Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Complement Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Europe Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Complement Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Complement Inhibitors Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Complement Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Complement Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Complement Factor D Inhibitor
  • Complement Factor B Inhibitor
  • Complement C5 Inhibitors
  • Complement C3 Inhibitors
  • C1 Esterase Inhibitors
Applications
  • Geographic Atrophy (GA)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Others
Companies covered
  • Alexion Pharmaceuticals
  • Amgen
  • Apellis Pharmaceuticals
  • Astellas Pharma
  • CSL Behring
  • Pharming Healthcare
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • UCB
  • Roche
  • Novartis
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Complement Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Complement Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Complement Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Complement Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Complement Inhibitors Market Dynamics
  1. 2.1 Complement Inhibitors Industry Trends
  2. 2.2 Complement Inhibitors Industry Drivers
  3. 2.3 Complement Inhibitors Industry Opportunities and Challenges
  4. 2.4 Complement Inhibitors Industry Restraints
3 Complement Inhibitors Market by Manufacturers
  1. 3.1 Global Complement Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Complement Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Complement Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Complement Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Complement Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Complement Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Complement Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Complement Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Complement Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Complement Inhibitors Tier 1, Tier 2, and Tier 3
4 Complement Inhibitors Market by Type
  1. 4.1 Complement Inhibitors Type Introduction
  2. 4.1.1 Complement Factor D Inhibitor
  3. 4.1.2 Complement Factor B Inhibitor
  4. 4.1.3 Complement C5 Inhibitors
  5. 4.1.4 Complement C3 Inhibitors
  6. 4.1.5 C1 Esterase Inhibitors
  7. 4.2 Global Complement Inhibitors Sales by Type
  8. 4.2.1 Global Complement Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Complement Inhibitors Sales by Type (2021-2032)
  10. 4.2.3 Global Complement Inhibitors Sales Market Share by Type (2021-2032)
  11. 4.3 Global Complement Inhibitors Revenue by Type
  12. 4.3.1 Global Complement Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Complement Inhibitors Revenue by Type (2021-2032)
  14. 4.3.3 Global Complement Inhibitors Revenue Market Share by Type (2021-2032)
5 Complement Inhibitors Market by Application
  1. 5.1 Complement Inhibitors Application Introduction
  2. 5.1.1 Geographic Atrophy (GA)
  3. 5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  4. 5.1.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  5. 5.1.4 Others
  6. 5.2 Global Complement Inhibitors Sales by Application
  7. 5.2.1 Global Complement Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Complement Inhibitors Sales by Application (2021-2032)
  9. 5.2.3 Global Complement Inhibitors Sales Market Share by Application (2021-2032)
  10. 5.3 Global Complement Inhibitors Revenue by Application
  11. 5.3.1 Global Complement Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Complement Inhibitors Revenue by Application (2021-2032)
  13. 5.3.3 Global Complement Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Complement Inhibitors Sales by Region
  1. 6.1 Global Complement Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Complement Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Complement Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Complement Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Complement Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Complement Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Complement Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Complement Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Complement Inhibitors Revenue by Region
  1. 7.1 Global Complement Inhibitors Revenue by Region
  2. 7.1.1 Global Complement Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Complement Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Complement Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Complement Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Complement Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Complement Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Complement Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Complement Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Complement Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Complement Inhibitors Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Complement Inhibitors Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Apellis Pharmaceuticals
  14. 8.3.1 Apellis Pharmaceuticals Company Information
  15. 8.3.2 Apellis Pharmaceuticals Business Overview
  16. 8.3.3 Apellis Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Apellis Pharmaceuticals Complement Inhibitors Product Portfolio
  18. 8.3.5 Apellis Pharmaceuticals Recent Developments
  19. 8.4 Astellas Pharma
  20. 8.4.1 Astellas Pharma Company Information
  21. 8.4.2 Astellas Pharma Business Overview
  22. 8.4.3 Astellas Pharma Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astellas Pharma Complement Inhibitors Product Portfolio
  24. 8.4.5 Astellas Pharma Recent Developments
  25. 8.5 CSL Behring
  26. 8.5.1 CSL Behring Company Information
  27. 8.5.2 CSL Behring Business Overview
  28. 8.5.3 CSL Behring Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CSL Behring Complement Inhibitors Product Portfolio
  30. 8.5.5 CSL Behring Recent Developments
  31. 8.6 Pharming Healthcare
  32. 8.6.1 Pharming Healthcare Company Information
  33. 8.6.2 Pharming Healthcare Business Overview
  34. 8.6.3 Pharming Healthcare Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pharming Healthcare Complement Inhibitors Product Portfolio
  36. 8.6.5 Pharming Healthcare Recent Developments
  37. 8.7 Regeneron Pharmaceuticals
  38. 8.7.1 Regeneron Pharmaceuticals Company Information
  39. 8.7.2 Regeneron Pharmaceuticals Business Overview
  40. 8.7.3 Regeneron Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron Pharmaceuticals Complement Inhibitors Product Portfolio
  42. 8.7.5 Regeneron Pharmaceuticals Recent Developments
  43. 8.8 Samsung Bioepis
  44. 8.8.1 Samsung Bioepis Company Information
  45. 8.8.2 Samsung Bioepis Business Overview
  46. 8.8.3 Samsung Bioepis Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Samsung Bioepis Complement Inhibitors Product Portfolio
  48. 8.8.5 Samsung Bioepis Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UCB Complement Inhibitors Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Roche Complement Inhibitors Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Complement Inhibitors Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Complement Inhibitors Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Takeda
  74. 8.13.1 Takeda Company Information
  75. 8.13.2 Takeda Business Overview
  76. 8.13.3 Takeda Complement Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Takeda Complement Inhibitors Product Portfolio
  78. 8.13.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Complement Inhibitors Value Chain Analysis
  2. 9.1.1 Complement Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Complement Inhibitors Production Mode & Process
  6. 9.2 Complement Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Complement Inhibitors Distributors
  9. 9.2.3 Complement Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst